The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025.
Biovian Oy announced a major investment of over €50 million to expand its manufacturing facility in Turku, Finland on July 26, 2023. The new facility plans to include house cutting-edge equipment and advanced technologies to support Advanced Therapy Medicinal Products (ATMP), such as adenoviral and adeno-associated viral (AAV) therapies.
According to the press release, it will feature dedicated Class A to D cleanroom areas for bulk drug substances and final drug product manufacture. Additionally, the expanded facility will follow current good manufacturing practices (cGMP) and fulfill both EU and US GMP requirements.
The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025. Further, the investment hopes to create 100 job opportunities in the region.
Source: Biovian
FDA Approves Pfizer Combination Regimen for Treating R/R Diffuse Large B-Cell Lymphoma
February 14th 2025The approval of an ADCETRIS combination regimen is based on positive data from a Phase III trial where the combination regimen demonstrated a clinically meaningful reduction in the risk of death.